# Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)

> **NCT02895815** · PHASE2 · WITHDRAWN · sponsor: **Janssen Pharmaceutical K.K.**

## Conditions studied

- Visual Acuity
- Geographic Atrophy
- Macular Degeneration

## Interventions

- **COMBINATION_PRODUCT:** CNTO 2476 (6.0 * 10^4 cells)
- **COMBINATION_PRODUCT:** CNTO 2476 (3.0 * 10^5 cells)

## Key facts

- **NCT ID:** NCT02895815
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-04-09
- **Primary completion:** 2021-02-20
- **Final completion:** 2022-08-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company business decision
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02895815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02895815, "Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02895815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*